Correction to: Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)

समान संसाधन

• Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
  द्वारा: Judge, Daniel P., और अन्य
  प्रकाशित: (2020)
• Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis
  द्वारा: Gillmore, Julian D, और अन्य
  प्रकाशित: (2015)
• Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines
  द्वारा: Benson, M D, और अन्य
  प्रकाशित: (2020)
• Strategies to improve the quality of life in patients with hereditary transthyretin amyloidosis (hATTR) and autonomic neuropathy
  द्वारा: Gendre, Thierry, और अन्य
  प्रकाशित: (2019)
• Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
  द्वारा: Zhang, Xiaoping, और अन्य
  प्रकाशित: (2019)